Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Calmangafodipir - PledPharma

Drug Profile

Calmangafodipir - PledPharma

Alternative Names: Aladote; PledOx; PP-095; PP-100; PP-100-01; SP-04 - Solasia Pharma

Latest Information Update: 16 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PledPharma
  • Developer PledPharma; Solasia Pharma; University of Milan Bicocca
  • Class Acetates; Chemoprotectants; Ethylenediamines; Hepatoprotectants; Pyridines; Small molecules
  • Mechanism of Action Antioxidants; Iron chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver failure
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chemotherapy-induced damage
  • Phase I/II Liver failure

Most Recent Events

  • 09 Oct 2019 Preclinical trials in Chemotherapy-induced damage in Italy (IV)
  • 09 Oct 2019 PledPharma and Solasia Pharma enters a second (extension) license agreement to co-promote and co-develop calmangafodipir in Japan, China, Hong Kong, Macau, South Korea and Taiwan for Chemotherapy induced damage (Chemotherapy induced peripheral neuropathy) caused by taxanes and any other chemotherapy (Prevention)
  • 09 Oct 2019 PledPharma announces intention to launch calmangafodipir in key Asian markets
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top